Fierce Pharma

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Data from AbbVie and Johnson & Johnson will fine-tune OpenFold3 in a confidentiality-preserving environment, powered by Apheris.

The future of pharmaceutical investment lies in the convergence of ESG principles with a strong emphasis on positive social contribution, ethical AI, and innovative business models. Companies that successfully navigate this landscape will be well-positioned to lead the industry in both financial performance and societal impact.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

In a recent interview with Fierce Biotech's Chris Hayden, Fortrea's Chief Technology and Data Officer Alaric Jackson discussed the growing role of AI in clinical trials. | Fortrea's CTO discusses AI's expanding role in clinical trials,

In a healthcare ecosystem where 5% of Google searches are health-related, small and medium-sized healthcare providers in India face an uphill battle. Competing with established brands while working with limited resources,

Looking ahead to 2025, small biopharma will continue its deliberate and ROI-driven approach to technology adoption. At the same time, the rise of open-source tools and accessible AI frameworks promises to level the playing field, offering smaller companies new opportunities to compete and innovate.

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I think ABSI stock is a good buy.